Analysis of the metabolic syndrome improvement with the orexin receptor antagonist
Not Applicable
- Conditions
- Metabolic syndrome with insomnia
- Registration Number
- JPRN-UMIN000027445
- Lead Sponsor
- Kochi University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 0
Inclusion Criteria
Not provided
Exclusion Criteria
The patients appeared harmful effect of suvorexant The patients prescribed with CYP3A inhibitory drugs
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method We will evaluate whether the patients fill the criteria of MS 6 months after suvorexant treatment. MS criteria is satisfied with abdominal circumference is higher than 85cm in male and 90cm in female, and with higher than two items in follows: (1) Dyslipidemia: triglyceride is higher than 150mg/dl and/or HDL cholesterol is lower than 40mg/dl. (2) Hypertension: systolic blood pressure is higher than 130mmHg and/or diastolic blood pressure is higher than 85mmHg. (3) Impaired glucose tolerance: fasting blood glucose is higher than 110mg/dl.
- Secondary Outcome Measures
Name Time Method